

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21165 A1

(51) International Patent Classification⁷: **A61K 31/045,**
31/05

Nitin [IN/US]; 788 Colonial Avenue, Pelham Manor, NY
10803 (US). LIPKIN, Martin [US/US]; 535 East 86th
Street, New York, NY 10028 (US).

(21) International Application Number: PCT/US00/25799

(22) International Filing Date:
20 September 2000 (20.09.2000)

(74) Agents: LICATA, Jane, Massey et al.; Law Offices of
Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053
(US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/155,019 21 September 1999 (21.09.1999) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): RUT-
GERS, THE STATE UNIVERSITY [US/US]; Old
Queens Building, Somerset and George Streets, New
Brunswick, NJ 08901 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): GHAI, Geeta
[US/US]; 250 Gallinson Drive, Murray Hill, NJ 07974
(US). HO, Chi-Tang [US/US]; 32 Jernee Drive, East
Brunswick, NJ 08816 (US). CHEN, Huang, Yu [CN/US];
4 Silverton Lane, Belle Mead, NJ 08502 (US). ROSEN,
Robert, T. [US/US]; 347 Harrier Drive, Monroe Town-
ship, NJ 08831 (US). WANG, Mingfu [CN/US]; 37
Marvin Lane, Piscataway, NJ 08854 (US). TELANG,

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: RESVERATROL ANALOGS FOR PREVENTION OF DISEASE

(57) Abstract: Compositions and methods for prevention or treatment of disease are provided which comprise analogs of Resvera-
trol.

WO 01/21165 A1

RESVERATROL ANALOGS FOR PREVENTION OF DISEASE

Background of the Invention

Naturally occurring non-nutritive agents such as flavonoids, phenolic compounds, glucosinulates, terpenes and many others present in plants are believed to have disease preventive properties. Diets containing some of these substances have been shown to be protective against diseases such as colon and breast cancer in animals (Kuo, S.M. 1997. *Clin. Rev. Oncogenesis* 8:47-69; Verhoeven et al. 1996. *Cancer Epid. Biomark. Prev.* 5:733-748; Bradlow et al. 1991. *Carcinogenesis* 12:1571-1574; Lamartiniere et al. 1995. *Proc. Soc. Exp. Biol. Med.* 208:120-123). The clinical relevance of such natural phytochemicals is dependent on extrapolation from epidemiological data and from experiments in animal models of diseases of interest.

Resveratrol (3,5,4'-trihydroxystilbene) and its glucoside, cis- and trans- forms occur naturally in foods such as grapes, mulberries, peanuts, and wine. Resveratrol and its related compounds also are found in other plants including a traditional Chinese medicinal plant, the dried roots of *Polygonum cuspidatum*. These polyphenolic compounds possess many biological activities including antioxidant activity, antimutagenic activity, antiinflammatory activity, anti-tumor promoting activity, as well as demonstrating a preventive effect for cancer (Jang et al. 1997. *Science* 275:218-220). Resveratrol has also been shown to affect a variety of specific cellular mediators. For example, studies have shown that resveratrol induces nitric oxide synthase (Hsieh et al. 1999. *Cancer Res.* 59:2596-2601), that resveratrol inhibits 12-O-tetradecanoylphorbol-13-acetate-induced cyclooxygenase-2 gene expression (Subbaramiah et al. 1998. *J. Biol. Chem.* 273:21875-21882), that resveratrol inhibits expression of

tissue factor and cytokines in vascular cells (Pendurthi et al. 1999. *Arterioscler. Thromb. Vasc. Biol.* 19:419-426), and that resveratrol inhibits ribonucleotide reductase and DNA synthesis in mammalian cells (Fontecave et al. 1998. *FEBS Lett.* 421:277-279).

Much attention has been focused on the fact that large amounts of resveratrol are present in red wine and that moderate red wine consumption may reduce the risk of cardiovascular disease (Goldberg et al. 1995. *Clin. Chim. Acta* 237:155-187). In addition, evidence has accumulated to support a role for resveratrol in prevention of cancer and heart disease (Constant, J. 1997. *Coron. Artery Dis.* 8:645-649; Fontecave et al. 1998. *FEBS Lett.* 421:277-279).

WO 9904747 describes the use of resveratrol to improve the appearance of human skin and to enhance differentiation and inhibit proliferation of keratinocytes. Resveratrol in pure form is given as a topical formulation in doses of 0.00002 to 10% resveratrol by weight.

WO 9903816 discloses compositions of resveratrol esters and their oligomers for use as anti-tumor and vasoprotective agents in animals and humans. The resveratrol derivatives are monomer or oligomers having at least one ester group with the formula -O-CO-A. None of the compounds are resveratrol analogs with hydroxyl or methoxy substitutions on the rings.

WO 9901148 describes compositions containing resveratrol and other polyphenols for the treatment of metabolic disorders such as anoxia. The polyphenols are extracts from grapes and grape products or wine with yeast extracts combined.

A Japanese patent (JP 9328410) discusses the use of an extract of the Yucca plant which contains saponin, flavone and resveratrol as a cosmetic for prevention of rough skin and cutaneous aging. The extract was shown to have antimicrobial activity as well as UV absorbing ability.

CN 1127070 describes use of resveratrol in combination with a variety of other compounds as additives for a

nutritional milk powder. The powder was developed for use in the elderly for immunostimulation and prevention of heart disease, as well as a milk powder for pregnant women and children and a health drink for athletes.

5 US Patent 5,747,536 discloses use of a trihydroxy or tetrahydroxystilbene, such as resveratrol, in combination with L-carnitine and alkanoyl L-carnitine to prevent or treat cardiovascular diseases, peripheral cardiopathies, and diabetic peripheral neuropathies.

10 Another Japanese patent (JP 61171427) describes use of an extract of *Polygonaceae* as an anti-thrombosis agent. The extract contains a stilbene compound comprising resveratrol as well as other components.

It has now been found that analogs of the natural
15 product resveratrol with additional hydroxy or methoxy substitutions have biological activity that can lead to disease prevention.

Summary of the Invention

20 An object of the present invention is composition comprising an analog of resveratrol, preferably a hydroxylated or methoxylated resveratrol including 3,5-dihydroxystilbene (R-1), 3, 3', 4, 5'-tetrahydroxystilbene (R-2), 3, 4, 4', 5-tetrahydroxystilbene (R-3), 3, 3', 5, 5'-tetrahydroxystilbene
25 (R-4), 3, 3', 4, 5, 5'-pentahydroxystilbene (R-5), 3, 5-dimethoxystilbene (MR-1), 3, 4', 5-trimethoxystilbene (MR-0), 3, 3', 4, 5'-tetramethoxystilbene (MR-2), 3, 4, 4', 5-tetramethoxystilbene (MR-3), 3, 3', 5' 5'-tetramethoxystilbene (MR-4), and 3, 3', 4, 5, 5'-pentamethoxystilbene (MR-5).

30 Another object of the present invention is a method for inhibiting cell growth comprising administering the composition.

Yet another object of the present invention is a method for preventing or treating cancer in an animal which comprises
35 administration of the composition.

Detailed Description of the Invention

Although there are reports of the biological activity and efficacy of resveratrol as a disease preventive agent, analogs of this compound have not been examined or described
5 as disease preventive agents. In the context of the present invention "analog" is a compound that is comprised of resveratrol with substituted groups attached to the parent compound to produce a chemically-modified resveratrol compound. Five hydroxy and six methoxy analogs of resveratrol
10 were synthesized using standard chemical methodology. Each analog is a novel analog that was then tested for biological activity. The analogs produced and tested included 3,5-dihydroxystilbene (R-1), 3, 3', 4, 5'-tetrahydroxystilbene (R-2), 3, 4, 4', 5-tetrahydroxystilbene (R-3), 3, 3', 5, 5'-
15 tetrahydroxystilbene (R-4), 3, 3', 4, 5, 5'-pentahydroxystilbene (R-5), 3, 5-dimethoxystilbene (MR-1), 3, 4', 5-trimethoxystilbene (MR-0), 3, 3', 4, 5'-tetramethoxystilbene (MR-2), 3, 4, 4', 5-tetramethoxystilbene (MR-3), 3, 3', 5' 5'-tetramethoxystilbene (MR-4), and 3, 3',
20 4, 5, 5'-pentamethoxystilbene (MR-5). The activity of the analogs was compared with that of the parent compound resveratrol (3, 4', 5-trihydroxystilbene) in several *in vitro* and *in vivo* models.

Initial tests examined the potential cancer preventive
25 activity of the analogs. Resveratrol and its analogs were evaluated in W138 and SV40 transformed W138VA cells and in preneoplastic 184-B5/HER and neoplastic SK-BR-3 human mammary epithelial cells. Cell proliferation, apoptosis, and gene expression studies were conducted using standard
30 methodologies.

W138 human diploid fibroblasts and cancerous SV40-transformed W138 cells (W138VA) were used in a cell proliferation assay. Growth rate and viability of these cells was determined following addition of each analog. Doses
35 tested ranged from 50 ng to 300 µg per ml or 1 µM to 100 µM

concentrations in culture media. Cell cultures were grown for 5 days in the presence of the various doses of analogs. Growth rate was measured by counting viable cells using the trypan blue dye exclusion method. Results are presented below in Table 1. Resveratrol inhibited cell growth at low concentrations, less than 10 μ M. When the analogs were tested, R-3 also inhibited cell growth but was 10-fold less effective than resveratrol. Methylation of resveratrol to form MR-0 did not significantly affect the ability of resveratrol to inhibit cell growth in W138VA cells, although MR-0 was less effective than resveratrol in W138 cells. Not all of the methylated analogs exhibited this differential growth inhibitory effect. Of the methylated analogs, MR-3 was most effective in inhibiting cell growth. At a concentration of 1 μ M, MR-3 completely blocked proliferation of W138VA cells, although it had no effect on growth of W138 cells. MR-1 was not active as an inhibitor of cell growth even at doses as high as 100 μ M. MR-4 inhibited growth of W138 cells but not W138VA cells at doses of 100 μ M. These data demonstrate that there are structure-activity differences between the analogs in terms of inhibition of cell proliferation.

25

30

Table 1 Growth Rate in Cells Following Exposure to Resveratrol Analogs		
Analog Tested	Cell Line	
	W138 Cells	W138VA Cells
R0 (10 μ M) ¹	+ ²	+
R1	ND ³	ND
R2	ND	ND
R3 (10 μ M)	+	+
R4	ND	ND
R5	ND	ND
MR0 (100 μ M)	+	+

	MR1 (100 μ M)	-- ⁴	--
	MR2	ND	ND
	MR3 (1 μ M)	--	+
	MR4 (100 μ M)	+	--
5	MR5 (100 μ M)	+	+
	¹ Value in parentheses is the effective concentration for growth inhibition. ² += >60% growth inhibition. ³ ND = not determined ⁴ --= no effect or only slight inhibition observed		

15

In addition to inhibition of cell growth, treatment of W138 and W138VA cells with analogs led to morphological changes in the cells. Treatment of W138 cells with resveratrol and its analogs R-1 and R-3 led to elongation of normal W138 cells. Methoxy analogs such as MR-0 and MR-3 caused the flattening of W138 cells. The flattening of the cells was accompanied by an increase in neutral β -galactosidase activity as indicated by an increase in staining. An increase in activity of β -galactosidase is characteristic of senescent cells, indicating that these analogs modulate the life-span of normal cells.

Resveratrol and its analogs were also tested in 184-B5/HER cells. Results showed that there was a dose-dependent inhibition of growth in response to treatment with resveratrol as well as the methoxy derivatives MR-0, MR-2 and MR-3. The concentration that inhibited growth by 50% (IC_{50}) for the tested compounds were: Resveratrol, 10.5 μ M; MR-0, 10.5 μ M; MR-2 120 μ M; MR-3, 1.0 μ M. A cell cycle analysis revealed that treatment with MR-0, MR-2 and MR-3 resulted in progressive arrest of cell in the G2/M phase relative to solvent-treated control cultures and that MR-3 was the most effective compound.

The effect of the analogs on apoptosis was also examined. Apoptosis is characterized by nuclear DNA fragmentation that is mediated through a variety of signal transduction pathways. An assay was used that relies on
5 fluorescent labeling of fragmented DNA. Results showed that R-3 induced apoptosis in W138VA cells, but not in W138 cells. In 184-B5/HER cells, resveratrol, MR-0 and MR-2 induced apoptosis to a significantly greater extent than solvent-treated control cells, while MR-3 had no effect on apoptosis.

10 Cell colony formation was also examined in 184-B5/HER cells. Consistent with the effect on cell cycle progression and apoptosis, resveratrol, MR-0, MR-2 and MR-3 exhibited differential inhibition of colony formation in response to continuous treatment with a 4 μ M dose of each analog.
15 Resveratrol, MR-0 and MR-2 produced approximately 25-40% inhibition in the anchorage-dependent colony formation assay. MR-3, however, produced almost a 80% inhibition of colony formation.

Targeted gene assay was then performed using RT-PCR.
20 Both normal (W138) and cancerous (W138VA) cells at resting phase (G0) were treated with 10-15% fetal bovine serum to initiate growth stimulation. Cells were then harvested at various time points during cell cycle progression. Total RNA was prepared from these cells according to standard RT-PCR
25 methods. Paired gene specific primers were prepared and used including human glyceraldehyde-3-phosphate dehydrogenase (HG3PDH), c-fos, c-myc, ornithine decarboxylase (ODC), proliferating cell nuclear antigen (PCNA), thymidine kinase (TK), cyclooxygenase 2 (COX2), BRCA1, BRCA2, p53, APC, MCC,
30 pRb, cyclooxygenase 1 (COX1), bcl2, and Bax. Results showed that expression of HG3PDH, a housekeeping gene, remained constant throughout the progression of the cell cycle in the control cells. Treatment with resveratrol or MR-3 did not affect the expression. Expression of c-fos and c-myc, an
35 early G1 event in normal W138 cells, were both deregulated in

transformed W138VA cells. Treatment with resveratrol and MR-3 did not significantly affect the expression of these two genes. Similarly, treatment of cells, both normal and transformed, with either resveratrol or MR-3 had no effect on
5 expression of ODC, PCNA, or TK genes (all cell cycle dependent genes). MR-3 stimulated the expression of COX2 in W138VA cells but not in W138 cells.

Both resveratrol and MR-3 completely abolished expression of BRCA1 and BRCA2 genes in human cells at all time
10 points examined. At equal doses, MR-3 was more potent than resveratrol in inhibiting expression of BRCA genes. Both BRCA1 and BRCA2 are breast cancer genes that together appear to be responsible for more than 60% of total hereditary breast cancers. Therefore, resveratrol and its analogs appear to
15 modulate the breast cancer genes.

The *in vivo* tumor inhibitory effects of MR-3 were tested in an orthotransplant model. Mice were transplanted with an oncogene expression preneoplastic breast epithelial cells. Mice were then divided into groups with the control group fed
20 AIN-76A diet alone. Another group of mice was fed AIN-76A diet supplemented with 400 ppm MR-3. After 12 weeks of continuous feeding, all mice in the control group exhibited palpable tumor formation at the transplant sites (100% tumor incidence). In contrast, the group fed diet supplemented with
25 the analog MR-3 had a 20% tumor incidence, with only one mouse of the five tested exhibiting tumor growth. Weight gains in the groups were comparable indicating that the analog had little toxicity.

These studies both *in vitro* and *in vivo* indicate that
30 analogs of resveratrol have biological activity related to preventing progression of cancer in cells.

In the present invention, analogs of resveratrol can be synthesized in the laboratory or prepared as extracts from plant material, as many resveratrol analogs are known in
35 nature. Animal diets and human or animal dietary supplements

can be prepared using the chemically synthesized analog or the plant extract material. One of skill would be able to extract plants material and isolate analogs based on the structures provided in the instant invention for active resveratrol
5 analogs.

To examine the activity of resveratrol-related plant extracts, roots of *Polygonum cuspidatum* were extracted and purified. The final extract prepared was 30% resveratrol which contained 16% trans- and 22% cis- resveratrol, 45%
10 piceid, and 40% stilbenes that contained 22% trans-piceid, 2% cis-piceid, 8% trans-resveratrol, and 8% cis-resveratrol. The inhibitory effect of these three fractions on DNA and RNA synthesis in HL-60 cells and the metabolism of DBMA by mouse liver microsomes was then examined.

15 All three fractions inhibited DNA and RNA synthesis in a dose-dependent manner. Increasing doses of each fraction reduced the uptake of radioactive thymidine and uridine into DNA and RNA of HL-60 cells. The three fractions had similar potency. All three fractions also inhibited DBMA metabolism
20 by mouse liver microsomes in a dose-dependent manner, with similar potency. These results provide evidence that natural plant extracts can be tested for potential biological activity as compared to resveratrol. Purified resveratrol analogs extracted from plants could be tested in similar experiments.

25 These data on resveratrol and its hydroxylated and methoxylated analogs support the development of foods and dietary supplements which comprise resveratrol or its analogs for animal consumption. For purposes of the present invention by "animal" it is meant to include humans. These foods and
30 supplements are referred to by those of skill in the art as "nutraceuticals". Compositions of the instant invention would be useful as nutraceuticals for prevention or treatment of diseases associated with cellular proliferation that would include but not be limited to cancer. In a preferred
35 embodiment, the analogs would be used to prevent or treat

colon, breast or prostate cancer. One of skill would be able to use the results of experiments in cells and animals to determine effective amounts to be administered to other animals, including humans. By "effective amount" it is meant
5 a concentration that inhibits cellular proliferation either *in vitro* in cells or *in vivo* in animals. For example, human test doses can be extrapolated from effective doses in cell studies, such as IC_{50} values, or from effective doses *in vivo* by extrapolating on a body weight or surface area basis. Such
10 extrapolations are routine in the art.

Compositions comprising resveratrol and its analogs can be formulated for administration as a food supplement using one or more fillers. Alternatively, compositions comprising these extracts can be administered as conventional
15 pharmaceuticals using one or more physiologically acceptable carriers or excipients. Nutraceutical compositions can be formulated for administration by any route including, but not limited to, inhalation or insufflation (through mouth or nose), oral, buccal, parenteral, vaginal, or rectal
20 administration. In one embodiment, oral administration, the compositions are added directly to foods and ingested as part of a normal meal. Various methods are known to those skilled in the art for addition or incorporation of nutraceuticals into foods.

25 Compositions for use in the present invention can also be administered in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. Examples of specific
30 compounds for use in formulating tablets and capsules are described in detail in the U.S. Pharmacopeia. Tablets comprising the extract can also be coated by methods well known in the art. Liquid preparations for oral administration can also be used. Liquid preparations can be in the form of
35 solutions, syrups or suspensions, or a dry product for

reconstitution with water or another suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles, 5 and preservatives. Again, specific additives are well known to those of skill and are listed in places such as the U.S. Pharmacopeia. In one embodiment, the oral preparation is formulated to provide controlled time release of the active nutraceutical components. For buccal administration the 10 extract can be formulated as a tablet or lozenge.

For administration by inhalation, compositions for use in the present invention can be delivered in the form of an aerosol spray in a pressurized package or as a nebulizer, with use of suitable propellants. In the case of a pressurized 15 aerosol, the dosage unit can be determined by providing a valve to deliver a metered dose.

Parenterally administered compositions are formulated to allow for injection, either as a bolus or as a continuous infusion. Formulations for injection can be prepared in unit 20 dosage forms, such as ampules, or in multi-dose units, with added preservatives. The compositions for injection can be in the form of suspensions, solutions, or emulsions, in either oily or aqueous vehicles. They may also contain formulatory agents such as suspending agents, stabilizing agents, and/or 25 dispersing agents. The active ingredient may also be presented in powder form for reconstitution with a suitable vehicle before use. Specific examples of formulating agents for parenteral injection are found in the U.S. Pharmacopeia.

For rectal administration or vaginal administration, 30 compositions for use in of the present invention can be formulated as suppositories, creams, gels, or retention enemas.

For dietary supplements, the extract can be added in concentrations up to 5% by weight and mixed according to 35 methods routine in the art. Dietary supplements for animals

can be prepared in a variety of forms including, but not limited to, liquid, powder, or solid pill forms.

The efficacy of resveratrol analogs appears to be enhanced by increasing hydrophobicity of the parent
5 resveratrol molecule with hydroxylation and/or methoxylation. One of skill would choose appropriate analogs for testing based on the results presented above for hydroxylated and methoxylated analogs. For example, the analogs would be tested first in vitro for activity in cells and then in vivo for
10 whole animal activity. The analogs with pharmacological activity both *in vitro* and *in vivo* would then be tested for therapeutic activity. Analogs would be administered to animals either alone or in combination, where combining analogs would lead to synergistic effects of the resveratrol-
15 related analogs. The combined therapy is supported by results showing that analogs have effects on different stages of the cell cycle and on expression of different gene products.

In the present invention, resveratrol and its analogs can administered either alone or in combination with other
20 compounds/phytochemicals known to affect cellular proliferation and tumor cell growth, where combining compounds would lead to synergistic effects. Compounds or extracts that could be used in combination with resveratrol analogs would include resveratrol itself, which has been shown in the
25 experiments discussed above to be effective in inhibiting tumor cell growth. Many plants, such as Mexican Bamboo and Huzhang, contain high amounts of resveratrol. Resveratrol is a well-known biologically active phytochemical, as shown in experiments where activity of resveratrol was tested as well
30 as the analogs. In addition to resveratrol, other compounds or extracts which could be used in combination with resveratrol analogs would include but not be limited to rosemary extract, black tea extracts, Mexican Bamboo extracts, and Huzhang extracts.

Extracts of rosemary have been shown to have anti-tumor activity and chemopreventive properties (Huang et al. 1994. *Cancer Res.* 54:701-708; Tokuda et al. 1986. *Cancer Lett.* 33:279-285; Singletary et al. 1996. *Cancer Lett.* 104:43-48; 5 Singletary, K.W. and J.M. Nelshoppen. 1991. *Cancer Lett.* 60:169-175). For example, a diet containing 1% of rosemary extract significantly inhibited the initiation of mammary tumorigenesis in rats (Singletary, K.W. and J.M. Nelshoppen. 1991. *Cancer Lett.* 60:169-175). Palpable tumor incidence in 10 rats fed the rosemary extract was 47% less than that of rats fed a control diet. Therefore, rosemary extracts were cancer preventive.

Black tea and its extracts also have been well-studied as potential pharmacological agents. Epidemiological studies 15 have suggested that tea consumption has a protective effect against certain forms of human cancer (Stoner, G.D. and H. Mukhtar. 1995. *J. Cell Biochem. Suppl.* 22:169-180; Fujiki et al. 1996. *Nutr. Rev.* 54:S67-S70). In addition, extracts of black tea in particular have been shown to be potent 20 inhibitors of tumorigenesis in several animal model systems (Javed et al. *Biomed. Environ. Sci.* 11:307-313; Yang et al. 1997. *Carcinogenesis* 18:2361-2365; Weisberger et al. 1998. *Carcinogenesis* 19:229-232; Rogers et al. 1998. *Carcinogenesis* 19:1269-1273). Therefore, black tea extracts are known to be 25 tumor preventive agents.

One of skill would use the knowledge of the biological activity of these other phytochemicals to develop a combination diet or dietary supplement for use to treat or prevent cancer in animals, including humans. Resveratrol 30 analogs may be used in combinations singly or multiply with resveratrol, Mexican Bamboo extract, Huzhang extract, rosemary extract, and black tea extracts. Doses of each compound or extract used in the combination product would be chosen based on known activity of the compound or extract in animals or

cells. It is routine for one of skill to extrapolate doses for use *in vivo* in humans based on studies in cells or animals. For example, human test doses can be extrapolated from effective doses in cell studies, such as IC_{50} values, or
5 from effective doses *in vivo* by extrapolating on a body weight or surface area basis. Again, one of skill in the art would know how to formulate the combined extracts based on the chemical nature of the extract and the desired effect.

The following non-limiting examples are provided to
10 further illustrate the present invention.

EXAMPLES

Example 1: Isolation and Purification of Analogs from Plant Material

15 Roots of a plant are repeatedly extracted with 75% methanol (10 x 4L) at 45°C. The ethanol extract is filtered and concentrated under vacuum using rotary evaporation (Rotavapor R-110, Buchi, Switzerland) to obtain a solid material. The concentrated material can then be either
20 partitioned with acidified ethyl acetate (3% hydrochloric acid) or pretreated with Amberlite resin and then loaded onto a polyamide column (10.16 x 124.46 cm), and gradient-eluted with methanol. Extract fractions are collected and identified by comparison with known analog structures.

25

Example 2: Treatment with Resveratrol Analogs

Azoxymethane (AOM)-induced colon tumorigenesis was produced according to the procedure of Deschner et al. (1992. *Carcinogenesis* 12:1193-1196) with slight modification. Female
30 CF-1 mice (6-7 weeks of age) were given subcutaneous injections of AOM (10 mg/kg) in 100 μ l normal saline once a week for 6 weeks. In the first experiment, the mice in group 1 and 2 were given AIN 76A diet and the mice in group 3 were given 2% rosemary extract in AIN 76A diet beginning at 2 weeks

before the first dose of AOM. In experiment 2, the mice in groups 1 and 2 were given AIN 76A diet for the entire experiment period, the mice in group 3 were given 0.5% rosemary in AIN 76A diet and in group 4 were given 2% rosemary in AIN 76A diet beginning at 2 week before the first dose of AOM, during, and continuing until 1 week after the last dose of AOM. The mice in group 5 were given 0.5% rosemary in AIN 76A diet and in group 6 were given 2% rosemary in AIN 76A diet beginning at 1 week after the last dose of AOM and continued until the end of the experiment. The mice were killed at 27 weeks after the last dose of AOM. Similar dosing regimens can be used for other types of extracts and in other models of tumorigenesis in animals.

What is claimed is:

1. A composition comprising an analog of resveratrol.
- 5 2. The composition of claim 1 wherein the analog comprises hydroxylated or methoxylated resveratrol.
3. The composition of claim 2 wherein the analog comprises 3,5-dihydroxystilbene (R-1), 3, 3', 4, 5'-
10 tetrahydroxystilbene (R-2), 3, 4, 4', 5-tetrahydroxystilbene (R-3), 3, 3', 5, 5'-tetrahydroxystilbene (R-4), 3, 3', 4, 5, 5'-pentahydroxystilbene (R-5), 3, 5-dimethoxystilbene (MR-1), 3, 4', 5-trimethoxystilbene (MR-0), 3, 3', 4, 5'-tetramethoxystilbene (MR-2), 3, 4, 4', 5-tetramethoxystilbene
15 (MR-3), 3, 3', 5' 5'-tetramethoxystilbene (MR-4), or 3, 3', 4, 5, 5'-pentamethoxystilbene (MR-5).
4. A method for inhibiting cell growth comprising administering the composition of claim 1.
- 20 5. The method of claim 4 wherein the composition comprises 3,5-dihydroxystilbene (R-1), 3, 3', 4, 5'-tetrahydroxystilbene (R-2), 3, 4, 4', 5-tetrahydroxystilbene (R-3), 3, 3', 5, 5'-tetrahydroxystilbene (R-4), 3, 3', 4, 5, 5'-pentahydroxystilbene (R-5), 3, 5-dimethoxystilbene (MR-1),
25 3, 4', 5-trimethoxystilbene (MR-0), 3, 3', 4, 5'-tetramethoxystilbene (MR-2), 3, 4, 4', 5-tetramethoxystilbene (MR-3), 3, 3', 5' 5'-tetramethoxystilbene (MR-4), or 3, 3', 4, 5, 5'-pentamethoxystilbene (MR-5).
- 30 6. A method for preventing or treating cancer in an animal comprising administering the composition of claim 1.
7. The method of claim 6 wherein the composition
35 comprises 3,5-dihydroxystilbene (R-1), 3, 3', 4, 5'-

tetrahydroxystilbene (R-2), 3, 4, 4', 5-tetrahydroxystilbene (R-3), 3, 3', 5, 5'-tetrahydroxystilbene (R-4), 3, 3', 4, 5, 5'-pentahydroxystilbene (R-5), 3, 5-dimethoxystilbene (MR-1), 3, 4', 5-trimethoxystilbene (MR-0), 3, 3', 4, 5'-
5 tetramethoxystilbene (MR-2), 3, 4, 4', 5-tetramethoxystilbene (MR-3), 3, 3', 5' 5'-tetramethoxystilbene (MR-4) or 3, 3', 4, 5, 5'-pentamethoxystilbene (MR-5).

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/US00/25799

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 31/045, 31/05 US CL : 514/730, 736 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 514/730, 736		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS, MEDLINE		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database CAPLUS on ACS. No. 2000:3327, BRETON et al. 'Use of hydroxystilbenes in a skin-fortifying composition'. FR 2777186 A1, 10 April 1998, see abstract.	1-3
Y	Database CAPLUS on ACS. No. 1992:511194, CUSHMAN et al. 'Synthesis and evaluation of analogs of (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as potential cytotoxic and antimitotic agents'. J. Med. Chem. 1992, Vol 35(12), 2293-306, see abstract.	4-7
A	US 5,747,536 A (CAVAZZA et al.) 05 May 1998 (05.05.98), see claims.	1-3
A	WO 99/04747 A1 (UNILEVER PLC) 04 February 1999, see abstract, and claims.	1-3
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"F" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search	Date of mailing of the international search report	
17 NOVEMBER 2000	28 DEC 2000	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer JENNIFER KIM Telephone No. (703) 305-1235	

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US00/25799**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99/01148 A1 (LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPARMA S.P.A.) 14 January 1999, see abstract.	1-3